LONDON, UK (GlobalData), 3 October 2013 - The growing prevalence of chronic diseases and an increasing elderly population will boost the Greek pharmaceutical market, which will increase from approximately $7.8 billion in 2013 to $8.2 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 0.6%, forecasts research and consulting firm GlobalData.
According to the company’s latest report*, the Greek pharmaceutical market was valued at $7.5 billion in 2007; but, following the recent economic crisis, net public pharmaceutical expenditure saw a cumulative decline of $1.67 billion. This decline was due to amendments made to medicine prices, as well as changes to the reimbursement rates for Social Security Funds (SSFs) and to the regulation of wholesale and retail margins.
The medical device sector will also experience modest growth, from $907m in 2007 to $1.2 billion in 2020, at a CAGR of 2.7%. The major segments in 2012 were In Vitro Diagnostics (IVD) (20.8%), cardiovascular devices (11.6%), ophthalmic devices (9.7%), drug delivery devices (7.6%), and diagnostic imaging (7.4%).
Joshua Owide, Director of Healthcare Industry Dynamics, says: “As part of cost-containment measures, the Greek government is encouraging the use of generics with the aim that generics will eventually account for 50% of all medicines used in hospitals. As part of the economic reforms and austerity measures, nearly 95% of drug prices have been reduced by 20%.
“Furthermore, healthcare reforms in terms of reimbursement have led to an increase in the co-payments for certain chronic diseases, with rates ranging from 10% to 25%. These, along with other cost-containment measures, will restrict market growth.”
However, the Greek government has introduced several policies in order to strengthen its free healthcare system and help improve patients’ health outcomes and quality of life in the long run.
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece
This report provides information and analysis on the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
-ABOUT GLOBALDATA-
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@globaldata.com
Help employers find you! Check out all the jobs and post your resume.
